Sensorion 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Nawal Ouzren

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	7.2yrs
CEO 소유권	n/a
경영진 평균 재임 기간	3yrs
이사회 평균 재임 기간	4.8yrs

최근 관리 업데이트

Recent updates

CEO

Nawal Ouzren (46 yo)

7.2yrs

테뉴어

Mrs. Nawal Ouzren serves as an Independent Non-Executive Director at Croda International Plc since February 1, 2022. She has been Chief Executive Officer of Sensorion SA (Sensorion SAS) since April 12, 201...

리더십 팀

이름	위치	테뉴어	보상	소유권
Nawal Ouzren	CEO & Director	7.2yrs	데이터 없음	데이터 없음
Bernd Schmidt	Chief Technical Officer	less than a year	데이터 없음	데이터 없음
Geraldine Honnet	Chief Medical Officer	4.3yrs	데이터 없음	데이터 없음
Christine Bec	Head of CMC Gene Therapy	4.3yrs	데이터 없음	데이터 없음
Stephanie Filipe	Head of the Project Management Office	3yrs	데이터 없음	데이터 없음
Laurent Desire	Head of Preclinical Development	1.4yrs	데이터 없음	데이터 없음
Rachel Cooper	Head of Audiology	less than a year	데이터 없음	데이터 없음

3.0yrs

평균 재임 기간

경험이 풍부한 관리: RFM 의 관리팀은 경험 ( 3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Nawal Ouzren	CEO & Director	7.1yrs	데이터 없음	데이터 없음
Robert Dow	Member of Scientific Advisory Board	3.8yrs	데이터 없음	데이터 없음
Khalil Barrage	Interim Chair	4.9yrs	데이터 없음	데이터 없음
Cédric Moreau	Director	4.9yrs	데이터 없음	데이터 없음
Alain Fischer	Member of Scientific Advisory Board	3.8yrs	데이터 없음	데이터 없음
Julien Miara	Director	4.9yrs	데이터 없음	데이터 없음
Eric de La Fortelle	Independent Director	no data	데이터 없음	데이터 없음
John Furey	Independent Director	4.8yrs	데이터 없음	데이터 없음
Christine Petit	Chair of Scientific Advisory Board	6.1yrs	데이터 없음	데이터 없음
Hernán López-Schier	Member of Scientific Advisory Board	3.8yrs	데이터 없음	데이터 없음
Paul Avan	Member of Scientific Advisory Board	3.8yrs	데이터 없음	데이터 없음
Diane Lazard	Member of Scientific Advisory Board	3.8yrs	데이터 없음	데이터 없음

4.8yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 이사회: RFM 의 이사회는 경험(평균 재직 기간 4.8 년)으로 간주됩니다.

Sensorion 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Sensorion Announces Appointment of Laurene Danon as Chief Financial Officer

Sensorion SA, Annual General Meeting, May 29, 2024

Sensorion Appoints Federico Mingozzi as Non-Executive Director to the Board of Directors

Sensorion SA Appoints Bernd Schmidt as New Chief Technical Officer

Sensorion SA, Annual General Meeting, Dec 20, 2023

Sensorion SA, Annual General Meeting, May 31, 2022

Recent updates

Sensorion Announces Positive Recommendation From the Data Safety Monitoring Board (DSMB) Regarding the Continuation of NOTOXIS, its Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity

Sensorion Announces New Positive Secondary Efficacy Endpoints Data from Sens-401 Phase 2A Clinical Trial for the Preservation of Residual Hearing Loss

Sensorion Announces Appointment of Laurene Danon as Chief Financial Officer

Sensorion SA, Annual General Meeting, May 29, 2024

Sensorion SA has completed a Follow-on Equity Offering in the amount of €15.482057 million.

Sensorion Meets Primary Endpoint for Sens-401 Phase 2A Clinical Study for Residual Hearing Preservation

Sensorion SA to Report Fiscal Year 2023 Results on Mar 14, 2024

Sensorion Announces the Completion of Patient Inclusion in Phase 2A Clinical Trial of Sens-401 for Residual Hearing Preservation After Cochlear Implantation

Sensorion Appoints Federico Mingozzi as Non-Executive Director to the Board of Directors

Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate Sens-501 into a Phase 1/2 Clinical Trial in Some European Countries

Sensorion SA Appoints Bernd Schmidt as New Chief Technical Officer

Sensorion SA, Annual General Meeting, Dec 20, 2023

Sensorion SA announced that it has received €33.214286 million in funding from Sofimac Innovation SAS, The Invus Group, LLC, Redmile Group, LLC

Sensorion SA to Report Q2, 2023 Results on Sep 18, 2023

Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe

Sensorion Sa Submits Clinical Trial Application for Lead Gene Therapy Candidate Otof-Gt in the Uk

Sensorion Reports Positive Efficacy Data from SENS-401 Phase 2a Clinical Study

Sensorion SA Announces First Patient Enrolled in Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity

Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to Otof-Gt for the Treatment of Otoferlin Gene-Mediated Hearing Loss

Sensorion SA Announces Approval to Initiate amended Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity in France

Sensorion Announces First Patient Enrolled in Proof-of-Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Sensorion SA to Report First Half, 2022 Results on Sep 22, 2022

Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Sensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Sensorion SA, Annual General Meeting, May 31, 2022

Sensorion SA to Report Fiscal Year 2021 Results on Oct 31, 2022

Sensorion SA Updates on SENS-401 Phase 2 Trial in Sudden Sensorineural Hearing Loss

Sensorion Announces Regulators Approval for Sensorion’s Amendment to Phase 2 Audible-S Trial of SENS-401 in Sudden Sensorineural Hearing Loss

Sensorion and Cochlear to Begin First Clinical Trial of SENS-401 for Hearing Preservation in Combination with Cochlear Implantation

Sensorion Presents New Preclinical Data on SENS-401 at ARO 2021

Sensorion Announces Third Gene Therapy Collaboration with Institut Pasteur Targeting Important Pediatric and Adult Deafness Segments

Sensorion Announces Preclinical Data Demonstrating SENS-401's Potential to Preserve Residual Hearing After Cochlear Implantation

Sensorion Provides an Update on Plans and Progress in the Development of SENS-401 for the Prevention of Hearing Loss

Sensorion SA announced that it expects to receive €4.999999 million in funding from Sonova Holding AG

Sensorion and Novasep Announce Signature of A Gene Therapy Product Development and Manufacturing Agreement

Sensorion SA has completed a Follow-on Equity Offering in the amount of €31.0012 million.

CEO

테뉴어

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령